Orthovita plans European launch of injectable synthetic bone product early next year
This article was originally published in Clinica
Biomaterials company Orthovita is undertaking trials in Europe of an injectable synthetic bone for treating compression of the spine, a condition that affects 700,000 patients per year worldwide and is caused by osteoporosis, trauma and bone cancer.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.